Clinical trials: Influenza, completed
Influenza, Human
Evaluate Safety of GCFLU® Administered Intramuscularly in Healthy Vietnamese Volunteer Aged From 3 Years Old
An open label, non-comparative bridging study to evaluate the safety of GCFLU® (seasonal influenza vaccine) administered intramuscularly in healthy Vietnamese volunteer aged from 3 years old
- Trial name
- NCT02723812
- Testing
- GCFLU® Influenza vaccine (Split virion, Inactivated)
- Where
- Vietnam
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological Products
Pandemic Influenza, Influenza A Virus Infection
Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults
The purpose of this study is to test different adjuvanted vaccine formulations as a two-dose schedule in immunologically naïve adults against one vaccine formulation without adjuvant in terms of tolerance and immunogenicity…
- Conditions
- Pandemic Influenza, Influenza A Virus Infection, Orthomyxoviridae Infections
- Trial name
- NCT00457509
- Testing
- A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant, A/H5N1 inactivated, split-virion influenza vaccine
- Where
- 3 sites in Belgium
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Immunogenicity and Safety Evaluation of QIS in Healthy Subjects
The purpose of this study was to evaluate the antibody response to each of the four influenza vaccine strains included in the study vaccine, as measured by hemagglutination inhibition (HAI) at 4 weeks after the last dose of the…
- Trial name
- NCT04101435
- Testing
- AdimFlu-S (QIS)
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
Safety Issues
Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population
This study is to assess protectivity and safety of Quadrivalent Influenza Vaccine in Indonesian Population
- Trial name
- NCT03336593
- Testing
- Quadrivalent Influenza Vaccine, Trivalent Influenza Vaccine
- Where
- 3 sites in Indonesia
- Volunteers
- 810 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Influenza A Virus Infection
Confirmation of the Antiviral Effects of Midodrine Identified With a Gene Expression Signature-based Screening of Inluenza A Virus Infected Cells
Rationale: Classical antiviral therapies target viral proteins and are consequently subject to resistance. To counteract this limitation, alternative strategies have been developed that target cellular factors.
- Trial name
- FLUMED (NCT01546506)
- Testing
- Gutron® treatment
- Where
- 39 sites in France
- Volunteers
- 79 people
- Sponsor
- Hospices Civils de Lyon
Influenza
Study to Evaluate the Safety and Immunogenicity of Fluarix™ 2006/2007 in Adults Aged 18 Years or Above
Vaccination is currently the most effective mean of controlling influenza and preventing its complications and mortality in persons at risk.
- Trial name
- NCT00345904
- Testing
- Fluarix
- Where
- 4 sites in Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acellular Pertussis, Diphtheria
Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults
The current study will provide information for the use of Boostrix concomitantly with influenza vaccine in adults aged 19-64 years.
- Conditions
- Acellular Pertussis, Diphtheria, Tetanus
- Trial name
- NCT00385255
- Testing
- Fluarix®, Boostrix®
- Where
- 12 sites in United States
- Volunteers
- 1,726 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)
This trial is designed to assess the safety and immunogenicity of a prime-boost schedule of GSK Biologicals' investigational vaccine GSK2340272A in children aged between 3 and 17 years.
- Trial name
- NCT00964158
- Testing
- Pandemic influenza vaccine GSK2340272A
- Where
- 5 sites in Spain
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus Infection
This study will evaluate the efficacy, safety, and population pharmacokinetics of a single, oral dose of GP681 compared with placebo in patients aged 12 to 65 years with acute uncomplicated influenza virus infection
- Trial name
- NCT05474755
- Testing
- GP681 40mg
- Where
- China
- Volunteers
- 591 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Human Influenza
Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and Above
The present study is designed to confirm the safety and immunogenicity of cell-derived, trivalent, surface antigen, inactivated influenza vaccine in 2 age cohorts: 18 to ≤60 years and ≥61 years and the antibody response to each…
- Trial name
- NCT01880697
- Testing
- TIVc
- Where
- Germany
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
HIV Infections, H1N1 Influenza
Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV
The purpose of this study is to assess the safety and effectiveness (immune response) to a licensed H1N12009 influenza vaccine in HIV-infected adults. The study will enroll 150 adults (ages 20-59 years).
- Trial name
- NCT01002040
- Testing
- Arepanrix
- Where
- 4 sites in Canada
- Volunteers
- 150 people
- Sponsor
- University of British Columbia
Pregnancy
PregText: Feasibility of Monitoring Influenza Vaccine Safety in Pregnant Women Using Text Messaging
In this study, the investigators will prospectively assess fever rates and other adverse events in pregnant women after administration of inactivated influenza vaccine (IIV) using text messaging.
- Trial name
- NCT01974050
- Testing
- Text message surveillance
- Where
- United States
- Volunteers
- 166 people
- Sponsor
- Columbia University
Influenza, Human
Pharmacokinetic Characteristics of Subjects with Hepatic Insufficiency and Healthy Subjects
The objective of this multicenter, open, single-dose, parallel controlled, Phase I clinical study is to Evaluate a single oral ZX-7101A PK in subjects with varying degrees of (mild or moderate) liver insufficiency compared with…
- Trial name
- ZX-7101A-203 (NCT05711797)
- Testing
- ZX-7101A 80mg
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Nanjing Zenshine Pharmaceuticals
Influenza
Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in Infants
The aim of this study is to investigate the immunogenicity and safety of the inactivated split-virion vaccine in infants.
- Trial name
- NCT01494740
- Testing
- split-virion, non-adjuvanted vaccine of 7.5 μg, split-virion, non-adjuvanted H1N1 vaccine of 15 μg, split-virion, non-adjuvanted vaccine of seasonal influenza
- Where
- China
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Influenza A H1N1
Study of SAB-176 in Healthy Adult Participants
Healthy adult participants will be challenged with the H1N1 Influenza virus and then treated with either SAB-176 or placebo.
- Trial name
- NCT04850898
- Testing
- SAB-176
- Where
- United Kingdom
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- SAb Biotherapeutics, Inc.
Influenza
Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)
This trial is designed to assess the safety and immunogenicity of a prime-boost schedule of GSK Biologicals' investigational vaccine GSK2340272A in children aged between 6 and 35 months.
- Trial name
- NCT00971321
- Testing
- Pandemic influenza vaccine GSK2340272A
- Where
- 5 sites in Spain
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)
The purpose of the study is to get a better understanding of the natural and adaptive immune response to the flu virus and to compare the immune cell responses to FDA-licensed flu vaccines in nasal mucosal cells and in blood.
- Trial name
- NCT03028974
- Testing
- Fluzone®, FluMist®
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Stanford University
H1N1 Influenza
Serum and Bronchoalveolar Inflammatory Parameters in Patients With Severe Adult Respiratory Distress Syndrome
Mannose-binding lectin (MBL) plays an important role in the innate immune response. In addition to activating the complement, MBL can induce cytokine production and contribute to a deleterious inflammatory response with severe…
- Trial name
- ARDS (NCT03641690)
- Testing
- Empirical antimicrobial therapy
- Where
- France
- Volunteers
- 97 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Influenza Vaccination, Influenza
Assessment of Viral Shedding in Children Previously in Receipt of Multiple Doses of Live Attenuated Influenza Vaccine (LAIV) Compared to Influenza Vaccine-naïve Controls
LAIV shedding studies in children could be an important way to confirm whether impediments to viral replication do indeed explain these observed reductions in vaccine effectiveness(VE), whether prior vaccination has any influence…
- Conditions
- Influenza Vaccination, Influenza, Vaccination
- Trial name
- Flushed (NCT03104790)
- Testing
- Fluenz Tetra (The two groups are defined by immunisation history, all receive the same intervention in the study)
- Where
- 3 sites in United Kingdom
- Volunteers
- 373 people, healthy volunteers welcome
- Sponsor
- Public Health England
Pneumonia, Laboratory Confirmed Influenza
Flu Vaccine Against Childhood Pneumonia, Bangladesh
Pneumonia is the leading cause of child death worldwide. Data from Bangladesh indicates that influenza has a substantial association with pneumonia among children less than two years old.
- Trial name
- NCT01319955
- Testing
- Trivalent inactivated influenza vaccine
- Where
- Bangladesh
- Volunteers
- 3,508 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.